Shire reported a net income of $616 million in the second quarter of 2018, an increase of 156%, according to a press release.
Product sales grew by 6% in the quarter to $3.8 billion, led by immunology, internal medicine and ophthalmic products, the release said.
Shire’s board agreed in the second quarter to allow the company to be acquired by Takeda, a plan that is expected to close in the first half of 2019.
Uncategorized